AstraZeneca PLC · LSE:AZN
AstraZeneca — Shareholder Meeting (2008)
14 slides from AstraZeneca's shareholder meeting presentation, 2008
Slide 1: 2008 Annual General Meeting
Ast azeneca? 2008 Annual General Meeting
Slide 2: David Brennan, Chief Executive Officer
David Brennan Chief Executive Officer
Slide 3: Headline results full year 07
Headline results full year 07 2007 2006 Actual CER $m $m growth growth Sales 29,559 26,475 +12% +7% Operating profit 8,094 8,216 -1% -4% Operating profit 9,060 8,216 +10% +8% (excl restructuring and synergy costs) Reported EPS $3.74 $3.86 -3% -5% Restructuring $0.46 EPS (excl restructuring) $4.20 vs
Slide 4: First quarter highlights
First quarter highlights > Results on track > Motavizumab filing in US > Litigation settlement with Ranbaxy
Slide 5: Headline results first quarter 08
Headline results first quarter 08 1Q08 1Q07 Actual CER $m $m % % Sales 7,677 6,966 +10 +4 Operating Profit 2,257 2,170 +4 -5 Core* Operating Profit 2,765 2,274 +21 +12 Reported EPS $1.03 $1.02 +1 -9 Core* EPS $1.28 $1.07 +19 +9 * Excludes amortisation related to MedImmune ($109m), restructuring and
Slide 6: AstraZeneca strategy
AstraZeneca strategy “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Renew our Strengthen Grow the Re-shape behaviour the pipeline business the business and culture OUR VALUES
Slide 7: Strengthen the pipeline
Strengthen the pipeline “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Strengthen the pipeline
Slide 8: Grow the business
Grow the business “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Valued medicines Strengthen Grow the the pipeline business Products
Slide 9: Key brands
Key brands Onc Dally — § Seroquel XR> quetiapine WO, CRESTOR" Symbicort = = —— Nexiu esomeprazole
Slide 10: Emerging Markets
Emerging Markets India China
Slide 11: 2008 Annual General Meeting
Ast azeneca? 2008 Annual General Meeting
Slide 12: Re-shape the business
Re-shape the business “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Valued Customer-centric medicines mindset Strengthen Grow the Re-shape the pipeline business the business Products Patient Needs
Slide 13: Renew our behaviours and culture
Renew our behaviours and culture “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Valued Customer-centric Lean and agile medicines mindset organisation Renew our Strengthen Grow the Re-shape behaviour the pipeline business the business and culture Products Patient Ne
Slide 14: Measuring performance
Measuring performance Upper Quartile Industry Performance • Earnings per share • Dividends & share re-purchases • Total shareholder return Strengthen Strengthen the thepipeline pipeline Grow the business Strengthen the pipeline • The numberofofnew The number newdrugs drugsentering enteringthethe • S